Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Home
/
update
/
details

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

NextEdge Admin

19 Nov 2024

2 min 19 sec

AstraZeneca,Type 1 Diabetes,(Treg) cell therapy program

Quell Therapeutics has announced that AstraZeneca has selected a candidate for its Type 1 Diabetes (T1D) T-regulatory (Treg) cell therapy program. This milestone marks the first significant achievement under their 2023 collaboration to develop, manufacture, and commercialize engineered Treg cell therapies for T1D and Inflammatory Bowel Disease (IBD).

Following this milestone, AstraZeneca has exercised its exclusive option to license the therapy for further development, triggering a $10 million payment to Quell. AstraZeneca will now lead CTA/IND-enabling studies and clinical development, with Quell providing chemistry, manufacturing, and controls (CMC) support, including GMP supply for a first-in-human trial. Quell retains the option to co-develop the T1D therapy in the U.S., in exchange for additional milestone payments and higher royalties on U.S. sales.

“This milestone highlights the strong collaboration and integration of our teams, as well as early validation of our CAR-Treg cell therapy approach to autoimmune diseases,” said **Iain McGill**, CEO of Quell Therapeutics. He added that the progress complements Quell’s internal program in transplantation, QEL-001, and underscores the potential of their platform across autoimmune and inflammatory diseases.

Regina Fritsche Danielson, SVP at AstraZeneca, emphasized the importance of advancing this program, stating, “Type 1 Diabetes poses significant challenges, with no disease-modifying therapies available. Through this CAR-Treg program, we aim to harness the immune system to slow or halt disease progression.”

This collaboration represents a significant step forward in addressing unmet needs in autoimmune diseases.